Melane Sampson, Author at BioTuesdays

Developments

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that the FDA has granted NRC-100 Fast Track Designation as a standalone drug for the treatment of suicidal ideation in patients with depression, including bipolar...

August 11, 2025

Developments

FDA approves PharmaTher’s KETARx for surgical pain management

PharmaTher Holdings (QTCQB: PHRRF; CSE: PHRM) has announced that the FDA has approved its ketamine product, KETARx, for use in surgical pain management. According to PharmaTher, the approval positions the company to...

August 11, 2025

Developments

Modular announces next-gen Pivot insulin pump at ADCES

Modular Medicine (NASDAQ: MODD) has announced its participation at the Association of Diabetes Care & Education Specialists (ADCES) Conference, August 8 to 11, 2025, where it will debut a coming soon campaign for...

August 8, 2025

Developments

Orchestra launches FDA-approved study protocol expanding patient eligibility criteria

Orchestra BioMed (NASDAQ: OBIO) has announced the roll out of an FDA-approved protocol update that enables a significant expansion in patient eligibility criteria for enrollment of its BACKBEAT study evaluating AVIM...

August 8, 2025

Developments

IDMC gives Elicio green light to continue study of ELI-002 7P in PDAC

Elicio Therapeutics (NASDAQ: ELTX) has announced that the Independent Data Monitoring Committee (IDMC) has recommended that its Phase 2 AMPLIFY-7P study in mutant KRAS (mKRAS)-driven pancreatic ductal adenocarcinoma...

August 5, 2025

Developments

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to...

August 5, 2025

Feature

Light AI turning smartphones into portable diagnostic labs for infectious disease detection

Light AI (CBOE CA: ALGO; FSE: 0H6; OTCQB: OHCFF) is developing cutting-edge artificial intelligence (AI) to advance health diagnostics and wellness solutions through its proprietary technology platform. By applying AI...

August 5, 2025

Feature

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics

Bioxytran Inc. (OTCQB: BIXT) is pioneering the use of complex carbohydrate-based therapeutics to address urgent unmet medical needs in virology, cancer metastasis, and oxygen transport.

July 29, 2025

Developments

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition

VVT Med (TSXV: DXI.H) (formerly DXI Capital) announced that it has completed its previously announced acquisition of all of the outstanding securities of V.V.T. Med (VVT) and Exiteam Acquisition (EAC), according to the...

July 23, 2025

Developments

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives

Enveric Biosciences (NASDAQ: ENVB) announced that the U.S. Patent and Trademark Office (USPTO) has granted a second Notice of Allowance for novel compounds within its next-generation, non-hallucinogenic mescaline...

July 23, 2025

Author - Melane Sampson

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

FDA approves PharmaTher’s KETARx for surgical pain management

Modular announces next-gen Pivot insulin pump at ADCES

Orchestra launches FDA-approved study protocol expanding patient eligibility criteria

IDMC gives Elicio green light to continue study of ELI-002 7P in PDAC

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Light AI turning smartphones into portable diagnostic labs for infectious disease detection

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives

Subscribe